Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

20083,685 citationsJournal Articlebronze Open Access

Authors

Jan B. Vermorken · Antwerp University Hospital

Ricard Mesı́a · Institut Català d'Oncologia

Fernando Rivera · Marqués de Valdecilla University Hospital

Éva Remenár

Andrzej Kawecki · The Maria Sklodowska-Curie National Research Institute of Oncology

Sylvie Rottey · Ghent University Hospital

József Erfán · Jósa András Múzeum

Abstract

As compared with platinum-based chemotherapy plus fluorouracil alone, cetuximab plus platinum-fluorouracil chemotherapy improved overall survival when given as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck. (ClinicalTrials.gov number, NCT00122460.)

Topics & Keywords

Head and Neck Cancer Studies Peptidase Inhibition and Analysis Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 359, Issue 11, pp. 1116-1127

DOI: 10.1056/nejmoa0802656

Field-Weighted Citation Impact: 106.44